670 related articles for article (PubMed ID: 28233083)
1. Molecular markers in glioma.
Ludwig K; Kornblum HI
J Neurooncol; 2017 Sep; 134(3):505-512. PubMed ID: 28233083
[TBL] [Abstract][Full Text] [Related]
2. What is the clinical value of cancer stem cell markers in gliomas?
Dahlrot RH; Hermansen SK; Hansen S; Kristensen BW
Int J Clin Exp Pathol; 2013; 6(3):334-48. PubMed ID: 23412423
[TBL] [Abstract][Full Text] [Related]
3. Identification of A2B5+CD133- tumor-initiating cells in adult human gliomas.
Ogden AT; Waziri AE; Lochhead RA; Fusco D; Lopez K; Ellis JA; Kang J; Assanah M; McKhann GM; Sisti MB; McCormick PC; Canoll P; Bruce JN
Neurosurgery; 2008 Feb; 62(2):505-14; discussion 514-5. PubMed ID: 18382330
[TBL] [Abstract][Full Text] [Related]
4. Glioma stem cells are more aggressive in recurrent tumors with malignant progression than in the primary tumor, and both can be maintained long-term in vitro.
Huang Q; Zhang QB; Dong J; Wu YY; Shen YT; Zhao YD; Zhu YD; Diao Y; Wang AD; Lan Q
BMC Cancer; 2008 Oct; 8():304. PubMed ID: 18940013
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of stem cell marker CD133 determined by promoter methylation but not by immunohistochemical expression in malignant gliomas.
Wu X; Wu F; Xu D; Zhang T
J Neurooncol; 2016 Apr; 127(2):221-32. PubMed ID: 26757925
[TBL] [Abstract][Full Text] [Related]
6. A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
Jhaveri N; Agasse F; Armstrong D; Peng L; Commins D; Wang W; Rosenstein-Sisson R; Vaikari VP; Santiago SV; Santos T; Chen L; Schönthal AH; Chen TC; Hofman FM
Cancer Lett; 2016 Feb; 371(2):240-50. PubMed ID: 26683773
[TBL] [Abstract][Full Text] [Related]
7. [Phenotype of SHG-44 glioma stem cell spheres and pathological characteristics of their xenograft tumors].
Wu TF; Chen JM; Chen SS; Chen GL; Wei YX; Xie XS; Du ZW; Zhou YX
Zhonghua Zhong Liu Za Zhi; 2013 Oct; 35(10):726-31. PubMed ID: 24378091
[TBL] [Abstract][Full Text] [Related]
8. Molecularly based management of gliomas in clinical practice.
Rudà R; Pellerino A; Magistrello M; Franchino F; Pinessi L; Soffietti R
Neurol Sci; 2015 Sep; 36(9):1551-7. PubMed ID: 26194534
[TBL] [Abstract][Full Text] [Related]
9. The Role Played by SLUG, an Epithelial-Mesenchymal Transition Factor, in Invasion and Therapeutic Resistance of Malignant Glioma.
Oh SJ; Ahn EJ; Kim O; Kim D; Jung TY; Jung S; Lee JH; Kim KK; Kim H; Kim EH; Lee KH; Moon KS
Cell Mol Neurobiol; 2019 Aug; 39(6):769-782. PubMed ID: 31011939
[TBL] [Abstract][Full Text] [Related]
10. Glioma biology and molecular markers.
Cohen AL; Colman H
Cancer Treat Res; 2015; 163():15-30. PubMed ID: 25468223
[TBL] [Abstract][Full Text] [Related]
11. Fatty acid binding protein 7 as a marker of glioma stem cells.
Morihiro Y; Yasumoto Y; Vaidyan LK; Sadahiro H; Uchida T; Inamura A; Sharifi K; Ideguchi M; Nomura S; Tokuda N; Kashiwabara S; Ishii A; Ikeda E; Owada Y; Suzuki M
Pathol Int; 2013 Nov; 63(11):546-53. PubMed ID: 24274717
[TBL] [Abstract][Full Text] [Related]
12. Differential expression of stem cell markers in proliferating cells in glioma.
Rehfeld M; Matschke J; Hagel C; Willenborg K; Glatzel M; Bernreuther C
J Cancer Res Clin Oncol; 2021 Oct; 147(10):2969-2982. PubMed ID: 34170383
[TBL] [Abstract][Full Text] [Related]
13. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
[TBL] [Abstract][Full Text] [Related]
14. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
[TBL] [Abstract][Full Text] [Related]
15. Systematically characterize the clinical and biological significances of 1p19q genes in 1p/19q non-codeletion glioma.
Chai RC; Zhang KN; Chang YZ; Wu F; Liu YQ; Zhao Z; Wang KY; Chang YH; Jiang T; Wang YZ
Carcinogenesis; 2019 Oct; 40(10):1229-1239. PubMed ID: 31157866
[TBL] [Abstract][Full Text] [Related]
16. Predictive biomarkers in adult gliomas: the present and the future.
Thomas L; Di Stefano AL; Ducray F
Curr Opin Oncol; 2013 Nov; 25(6):689-94. PubMed ID: 24076583
[TBL] [Abstract][Full Text] [Related]
17. The role of glioma stem cells in glioma tumorigenesis.
Yin CL; Lv SQ; Chen XY; Guo H
Front Biosci (Landmark Ed); 2014 Jan; 19(5):818-24. PubMed ID: 24389226
[TBL] [Abstract][Full Text] [Related]
18. The stem cell/cancer stem cell marker ALDH1A3 regulates the expression of the survival factor tissue transglutaminase, in mesenchymal glioma stem cells.
Sullivan KE; Rojas K; Cerione RA; Nakano I; Wilson KF
Oncotarget; 2017 Apr; 8(14):22325-22343. PubMed ID: 28423611
[TBL] [Abstract][Full Text] [Related]
19. Novel Cancer Stem Marker and Its Applicability for Grading Primary Human Gliomas.
Dolgova EV; Mishinov SV; Proskurina AS; Potter EA; Efremov YR; Bayborodin SI; Tyrinova TV; Stupak VV; Ostatin AA; Chernykh ER; Bogachev SS
Technol Cancer Res Treat; 2018 Jan; 17():1533034617753812. PubMed ID: 29375020
[TBL] [Abstract][Full Text] [Related]
20. Molecular markers in gliomas: impact for the clinician.
Hofer S; Lassman AB
Target Oncol; 2010 Sep; 5(3):201-10. PubMed ID: 20809335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
